Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
guaifenesin + promethazine + sodium benzoate
- Development stage
- Unknown
- Lead developer
- Laboratoires Elerté
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TussiSédal is a combination pharmaceutical product developed by Laboratoires Élerté, primarily indicated for the symptomatic treatment of non-productive (dry) and irritating coughs, particularly those occurring in the evening or at night. The formulation consists of three active ingredients: promethazine, guaifenesin, and sodium benzoate. Promethazine is a first-generation H1-receptor antagonist and phenothiazine derivative that provides antitussive effects by suppressing the cough reflex and offers sedative properties to aid sleep. Guaifenesin and sodium benzoate function as expectorants, which help to thin bronchial secretions and facilitate their removal from the respiratory tract. This combination is commonly used in France and is available in both standard and sugar-free syrup formulations.
- Brand names
- TussiSédalTussiSédal sans sucre
- Other names
- TussiSédal Élerté
02
Targets
mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on guaifenesin + promethazine + sodium benzoate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on guaifenesin + promethazine + sodium benzoate.